Suppr超能文献

哮喘治疗的新治疗靶点和药物。

New Therapeutic Targets and Drugs for the Treatment of Asthma.

机构信息

Postgraduate Program in Natural Products and Synthetic Bioactive, Federal University of Paraiba, Joao Pessoa - PB, Brazil.

Federal University of Sao Francisco Valley, Juazeiro-BA, Brazil.

出版信息

Mini Rev Med Chem. 2018;18(8):684-696. doi: 10.2174/1389557517666170927145011.

Abstract

Asthma is an inflammatory disease which affects millions of people worldwide. Therefore, it is necessary to search for new sources of therapies for the treatment of these patients in order to improve their quality of life. From content analysis of literature of new therapeutic targets, there are various targets and drugs reported to be promising for the treatment of asthma. Interleukins involved in inflammatory processes are often presented as candidate targets for new drugs. The action of such therapeutics would not only affect interleukins, but also their receptors. Small molecules (e.g. ligustrazine and SP600125) and large molecule antibodies (e.g. lebrikizumab, benralizumab, dupilumab) are being considered as novel agents for the pharmacotherapy of asthma. Therefore, through this research, we can see advances in the search for new targets and promising drugs to treat asthma. It is expected that these new drug candidates will eventually be approved and marketed so that asthma patients can use them to enhance their quality of life.

摘要

哮喘是一种影响全球数百万人的炎症性疾病。因此,有必要寻找新的治疗方法来治疗这些患者,以提高他们的生活质量。从新治疗靶点的文献内容分析来看,有许多被报道具有治疗哮喘前景的靶点和药物。参与炎症过程的白细胞介素通常被认为是新药的候选靶点。这些治疗方法的作用不仅会影响白细胞介素,还会影响其受体。小分子(如川芎嗪和 SP600125)和大分子抗体(如 lebrikizumab、benralizumab、dupilumab)被认为是哮喘药物治疗的新型药物。因此,通过这项研究,我们可以看到寻找新的治疗靶点和有前途的药物治疗哮喘的进展。预计这些新的候选药物最终将获得批准并上市,以便哮喘患者可以使用它们来提高生活质量。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验